Editor's choice

European Endocrinology, 2015;11(1):21–5 DOI:10.17925/EE.2015.11.01.21

Latest Articles

European Endocrinology, 2015;11(1):26–31 DOI:10.17925/EE.2015.11.01.26
European Endocrinology, 2015;11(1):41–2 DOI:10.17925/EE.2015.11.01.41
European Endocrinology, 2015;11(1):45–6 DOI:10.17925/EE.2015.11.01.45

Latest Videos

Dr Grande (Hospital Universitario Ramón y Cajal, Madrid, Spain) talks to ecancertv at ESMO 2014 about his work looking at the use of vandetanib to treat thyroid cancer patients.
Pituitary Disorders including Prolactinomas in Pregnancy by Dr. Ganapathy Bantwal
Dr. Philipp Scherer talks about his Banting Medal for Scientific Achievement lecture on the role of adipose tissue in treatment of diabetes at the American Diabetes Association 2015 meeting in Boston.
Matthew Kulke, MD, of the Dana-Farber Cancer Institute explains why progressive free survival is a more appropriate outcome measure for clinical trials involving patients with neuroendocrine tumors.
One of the newest developments in the treatment of diabetes is the GLP-1 receptor agonist. With different forms intended for different populations it continues a longstanding pattern of bringing new...